Japan Bioproducts Industry Co.

Shibuya-ku, Japan

Japan Bioproducts Industry Co.

Shibuya-ku, Japan
SEARCH FILTERS
Time filter
Source Type

Wang W.,Dalian Medical University | Liu Q.,Dalian Medical University | Wang C.,Dalian Medical University | Meng Q.,Dalian Medical University | And 2 more authors.
Peptides | Year: 2011

To investigate the effect of JBP485 (an anti-inflammatory dipeptide) on PEPT1 in indomethacin-induced intestinal injury in rats and damage in Caco-2 cells, the activity and expression of PEPT1 were examined. The effects of treatment with indomethacin and co-treatment with JBP485 were examined in terms of intestinal histological changes, MDA and MPO levels in rats; as well as LDH-release and oxidative stress in Caco-2 cells. Uptake of glycylsarcosine (Gly-Sar) by PEPT1 was determined by in vivo, in vitro and in situ studies. RT-PCR and Western blot were used to assess the expression of PEPT1 in rat intestine and Caco-2 cells. JBP485 caused a significant decrease in MDA and MPO levels, and improved the pathological condition of rat intestine, while attenuating Caco-2 cells damage induced by indomethacin. Uptake of Gly-Sar by PEPT1 was decreased by indomethacin treatment, whereas the Gly-Sar plasma concentration was markedly increased in JBP485 co-treated rats. Indomethacin down-regulated the expression of PEPT1 mRNA and protein in rat intestine and Caco-2 cells, and the effects were reversed after administration of JBP485. These results indicated that JBP485 not only improved intestinal injury and cell damage but also partially blocked the down-regulation of PEPT1 expression and function induced by indomethacin. © 2011 Elsevier Inc. All rights reserved.


Liu Z.,Dalian Medical University | Wang C.,Dalian Medical University | Liu Q.,Dalian Medical University | Meng Q.,Dalian Medical University | And 4 more authors.
Peptides | Year: 2011

Cyclo-trans-4-l-hydroxyprolyl-l-serine (JBP485) is a dipeptide with anti-hepatitis activity that has been chemically synthesized. Previous experiments in rats showed that JBP485 was well absorbed by the intestine after oral administration. The human peptide transporter (PEPT1) is expressed in the intestine and recognizes compounds such as dipeptides and tripeptides. The purposes of this study were to determine if JBP485 acted as a substrate for intestinal PEPT1, and to investigate the characteristics of JBP485 uptake and transepithelial transport by PEPT1. The uptake of JBP485 was pH dependent in human intestinal epithelial cells Caco-2. And JBP485 uptake was also significantly inhibited by glycylsarcosine (Gly-Sar, a typical substrate for PEPT1 transporters), JBP923 (a derivative of JBP485), and cephalexin (CEX, a β-lactam antibiotic and a known substrate of PEPT1) in Caco-2 cells. The rate of apical-to-basolateral transepithelial transport of JBP485 was 1.84 times higher than that for basolateral-to-apical transport. JBP485 transport was obviously inhibited by Gly-Sar, JBP923 and CEX in Caco-2 cells. The uptake of JBP485 was increased by verapamil but not by cyclosporin A (CsA) and inhibited by the presence of Zn2+ or the toxic metabolite of ethanol, acetaldehyde (AcH) in Caco-2 cells. The in vivo uptake of JBP485 was increased by verapamil and decreased by ethanol in vivo, which was consisted with the in vitro study. PEPT1 mRNA levels were enhanced after exposure of the cells to JBP485 for 24 h, compared to control. In conclusion, JBP485 was actively transported by the intestinal oligopeptide transporter PEPT1. This mechanism is likely to contribute to the rapid absorption of JBP485 by the gastrointestinal tract after oral administration. © 2011 Elsevier Inc.


Liu T.,Dalian Medical University | Guo X.,Dalian Medical University | Meng Q.,Dalian Medical University | Wang C.,Dalian Medical University | And 5 more authors.
Peptides | Year: 2012

The objective was to determine whether protective effects of JBP485 on biliary obstruction induced by alpha-naphthylisothiocyanate (ANIT) are mediated by the organic anion transporters Oat1, Oat3 and the multidrug resistance-associated protein Mrp2. The ANIT-induced increases in bilirubin (BIL), alanine aminotransferase (ALT) and aspartate transaminase (AST) in rat serum were inhibited significantly by oral administration of JBP485. The plasma concentration of JBP485 which is the substrate of Oat1 and Oat3 determined by LC-MS/MS was markedly increased after intravenous administration in ANIT-treated rats, whereas cumulative urinary excretion of JBP485 in vivo and the uptake of JBP485 in kidney slices were decreased remarkably. RT-PCR and Western blot showed the decreased expression of Oat1 and Oat3, increased expression of Mrp2 in ANIT-induced rats, meanwhile, the expression levels of Mrp2 and Oat1 were up-regulated after administration of JBP485. The up-regulation of Mrp2 and Oat1 was associated with a concomitant increase in urinary BIL after treatment with JBP485 in ANIT-treated rats. The mechanism for JBP485 to restore liver function might be related to improvement of the expression and function for Oat1 and Mrp2 as well as facilitation of urinary excretion for hepatoxic substance. © 2012 Elsevier Inc.


Guo X.,Dalian Medical University | Meng Q.,Dalian Medical University | Liu Q.,Dalian Medical University | Wang C.,Dalian Medical University | And 3 more authors.
Peptides | Year: 2012

The purpose of this study was to construct stably transfected HeLa cells with human peptide transporters (hPEPT1/hPEPT2) and to identify the function of the transfected cells using the substrate JBP485 (a dipeptide) and a typical substrate for PEPTs, glycylsarcosine (Gly-Sar). An efficient and rapid method was established for the preparation and transformation of competent cells of Escherichia coli. After extraction and purification, hPEPT1/hPEPT2-pcDNA3 was transfected into HeLa cells by the liposome transfection method, respectively. HeLa-hPEPT1/hPEPT2 cells were selected by measuring the protein expression and the uptake activities of JBP485 and Gly-Sar. A simple and rapid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the simultaneous determination of JBP485 and Gly-Sar in biological samples. The Michaelis-Menten constant (K m) values of Gly-Sar uptake by the hPEPT1 and hPEPT2-expressing transfectants were 1.03 mM and 0.0965 mM, respectively, and the K m values of JBP485 uptake were 1.33 mM for PEPT1 and 0.144 mM for PEPT2. The uptake of Gly-Sar was significantly inhibited by JBP485 with a K i value of 8.11 mM (for PEPT1) and 1.05 mM (for PEPT2). Maximal uptake of Gly-Sar were detected at pH 5.8 (for PEPT1) and pH 6.5 (for PEPT2), suggesting that both HeLa-hPEPT1 and HeLa-hPEPT2 were H + dependent transporters. Stably transfected HeLa-hPEPT1/HeLa-hPEPT2 cells were constructed successfully, and the functions of hPEPT1/hPEPT2 were identified using their substrates, JBP485 and Gly-Sar. The transfected cells with transporters were used to investigate drug-drug interactions (DDIs) between JBP485 and other substrates (cephalexin or lisinopril) of PEPT1 and PEPT2. © 2012 Elsevier Inc. All rights reserved.


Cang J.,Dalian Medical University | Zhang J.,Dalian Medical University | Wang C.,Dalian Medical University | Liu Q.,Dalian Medical University | And 6 more authors.
Drug Metabolism and Pharmacokinetics | Year: 2010

To investigate the pharmacokinetics and mechanism of intestinal absorption of JBP485 in rats,the pharmacokinetics of JBP485 were investigated in vivo both intravenously and orally. The effects of glycylsarcosine (Gly-Sar) on the uptake and transepithelial transport of JBP485 were examined in everted intestinal sacs, in situ jejunal perfusion, Caco-2 cells and PEPT1 transfected Hela cells. The gastrointestinal absorption of JBP485 was rapid. T1/2β was 2.25±0.06 h, CLplasma was 2.99±0.002 ml/min/kg, Vd was 0.22±0.05 l/kg and bioavailability was about 30z at a dosage of 25 mg/kg. JBP485 underwent rapid distribution in the tissues. Gly-Sar significantly decreased JBP485 uptake and transport in these models. A kinetic study showed that JBP485 was transported by PEPT1 in Caco-2 cells with Km and Vmax values of 0.33±0.13 mM and 0.72±0.06 nmol/mg protein/10 min, respectively. JBP485 appeared to have linear pharmacokinetics at intravenous doses of 6.25-100 mg/kg with minor first-pass effect, and JBP485 was mainly distributed in the kidney; JBP485 is a substrate for PEPT1 which is involved in the absorption of JBP485 in rat intestine.


Meng Q.,Dalian Medical University | Liu Q.,Dalian Medical University | Wang C.,Dalian Medical University | Sun H.,Dalian Medical University | And 3 more authors.
Drug Metabolism and Pharmacokinetics | Year: 2010

Cefditoren, a third generation cephalosporin antibiotics, has been used in clinics extensively. Previous results have indicated that cefditoren is excreted into bile as unchanged form. To investigate whether canalicular membrane transporters of hepatocytes were involved in the biliary excretion of cefditoren, we examined the hepatobiliary disposition of cefditoren using probenecid, novobiocin and verapamil as inhibitors of Mrp2, Bcrp and P-gp respectively in perfused rat livers. The values for the hepatic extraction ratio had no statistical significance, whereas cumulative biliary excretion rates of cefditoren were significantly reduced to 43.8% and 79.5% over 25 min in the perfused probenecid and novobiocin rats, respectively. We further investigated the effects of cefditoren on the expression of hepatic transporters by RT-PCR and Western blot after oral administration of cefditoren one week. The expression levels of Mrp2, Bcrp, Oat2 mRNA were markedly increased, while P-gp and Oct1 mRNA were decreased. In concordance with RT-PCR results, Mrp2 expression level increased by Western blotting. These results indicate that Mrp2 and Bcrp may be involved in the biliary excretion of cefditoren. Cefditoren can up-regulate the expression levels of Mrp2, Bcrp and Oat2, and down-regulate P-gp and Oct1 mRNA expression. These results provide important data for drug-drug interactions.


Cang J.,Dalian Medical University | Wang C.,Dalian Medical University | Liu Q.,Dalian Medical University | Sun H.,Dalian Medical University | And 3 more authors.
Journal of Liquid Chromatography and Related Technologies | Year: 2011

A sensitive high performance liquid chromatography method (HPLC) has been developed to quantify JBP485, a dipeptide with antihepatitis activity in rat biological samples. Samples of plasma and bile were analyzed following a single-step method of protein precipitation with trichloroacetic acid (10%, v/v). JBP485 was separated on a reversed-phase Agilent TC-C18 column (5μm, 4.6×250mm) at 20°C. The mobile phase was comprised of methanol and water (5:95, v/v). Peaks eluting from the column were detected with an ultraviolet detector at a wavelength of 203nm. Standard curves were linear in the range 0.5-250g/mL and correlation coefficients are 0.999. The intra- and inter-day precision (RSD) did not exceed 4% and 5%, respectively. Extraction recovery was better than 82.08% in blood. The method was successfully applied to investigate JBP485 plasma pharmacokinetics in rats. JBP485 appeared to have a linear pharmacokinetic characterization within doses of 6.25-100mg/kg. The half-life is 2.32±0.16h, plasma clearance is 2.66±0.15mL/min/kg, volume of distribution is 0.18±0.01l/kg and accumulated billiary excretion of JBP485 is only 2% of the total dose. Copyright © Taylor & Francis Group, LLC.


Wang C.,Dalian Medical University | Cang J.,Dalian Medical University | Liu Q.,Dalian Medical University | Meng Q.,Dalian Medical University | And 5 more authors.
Chromatographia | Year: 2011

A rapid and selective liquid chromatographic/tandem mass spectrometric method for the determination of JBP485 was developed and validated. Following protein precipitation, the analyte and internal standard (JBP923) were separated from human plasma using an isocratic mobile phase on an Elite Kromasil C18 column. An API 3200 tandem mass spectrometer equipped with a Turbo ionSpray ionization source was used as the detector and operated in the positive ion mode. Multiple reaction monitoring using the precursor to product ion combinations of m/z 201.2 → 86.2 and m/z 219.2 → 86.2 was performed to quantify JBP485 and JBP923, respectively. The method was linear in the concentration range of 0.10-50.00 μg mL-1 using 100 μL of plasma. The lower limit of quantification was 0.10 μg mL-1. The intra- and inter-day relative standard deviations over the entire concentration range were less than 6.65%. Accuracy determined at three concentrations (0.25, 4.00 and 25.00 μg mL-1 for JBP485) ranged from -0.78 to 2.74% in terms of relative error. Each plasma sample was chromatographed within 2.0 min. The method was successfully applied to characterize the pharmacokinetic profiles of JBP485 in rats after an intravenous injection of 6.25 mg kg-1 JBP485. © 2011 Springer-Verlag.


Miao Q.,Dalian Medical University | Liu Q.,Dalian Medical University | Wang C.,Dalian Medical University | Meng Q.,Dalian Medical University | And 4 more authors.
Drug Metabolism and Pharmacokinetics | Year: 2011

The aim of this study was to investigate the pharmacokinetic mechanism of interaction between JBP485 and zinc. The plasma concentration of JBP485 after oral administration in vivo, the plasma concentration of JBP485 from the portal vein after jejunal perfusions in situ, the serosal fluid concentration of JBP485 in everted small intestine preparations and the uptake of JBP485 by HeLa-hPEPT1 cells in vitro were determined by LC-MS/MS. RT-PCR and Western blotting were used to determine the mRNA and protein levels of Pept1 in the intestinal mucosa. The AUCs of JBP485 in in vivo, in vitro and in situ studies were significantly decreased after zinc pre-administration. Kinetic analysis showed that zinc inhibits the uptake of JBP485 by decreasing the affinity of JBP485 for PEPT1 in HeLa-hPEPT1 cells. RT-PCR and Western blotting indicated that zinc had no effect on basal intestinal Pept1 expression. Our results are novel in demonstrating for the first time that zinc ions, but not zinc gluconate, can inhibit the transport activity of PEPT1. In addition, the uptake of JBP485 was not affected by changes in pH values after zinc treatment. Zinc decreases the absorption of JBP485 by inhibiting the transport activity of PEPT1; however, basal intestinal Pept1 expression does not change. © 2011 by the Japanese Society for the Study of Xenobiotics (JSSX).


Guo X.,Dalian Medical University | Meng Q.,Dalian Medical University | Liu Q.,Dalian Medical University | Wang C.,Dalian Medical University | And 5 more authors.
Drug Metabolism and Pharmacokinetics | Year: 2012

The purpose of this study was to clarify the pharmacokinetic mechanism of interaction between JBP485 (cyclo-trans-4-L-hydroxyprolyl-L-serine, a dipeptide with antihepatitis activity) and lisinopril (an angiotensin-converting enzyme inhibitor) in vitro and in vivo. When JBP485 and lisinopril were administered orally simultaneously, the plasma concentrations of the two drugs were decreased significantly, but few changes were observed after simultaneous intravenous administration of the two drugs. The uptake of JBP485 and lisinopril in everted intestinal sacs and in HeLa cells transfected with human peptide cotransporter 1 (PEPT1), as well as absorption of JBP485 and lisinopril after jejunal perfusion were reduced after simultaneous drug administration, which suggested that the first target of drug interaction was PEPT1 in the intestine during the absorption process. The cumulative urinary excretions and renal clearance of the two drugs were decreased after intravenous co-administration, while uptakes of the two drugs in kidney slices and hOAT1/hOAT3-transfected HEK293 cells were decreased. These results indicated that the second target of drug-drug interaction was located in the kidney. These findings confirmed that the pharmacokinetic mechanism of interaction between JBP485 and lisinopril could be explained by their inhibition of the same transporters in the intestinal mucosa (PEPT1) and kidneys (OATs). © 2012 by the Japanese Society for the Study of Xenobiotics (JSSX).

Loading Japan Bioproducts Industry Co. collaborators
Loading Japan Bioproducts Industry Co. collaborators